

A34586 (070050.1668)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Fisher *et al.*
Serial No. : 09/648,310 Examiner: Yu, M.
Filed : August 25, 2000 Group Art Unit: 1642
For : PROGRESSION SUPPRESSED GENE 13 (PSGen13) AND USES
THEREOF

INFORMATION DISCLOSURE STATEMENT


I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313-1450

July 30, 2003

Date of Deposit

Lisa B. Kole

Attorney Name


Signature35.225

PTO Registration No.

July 30, 2003

Date of Signature

#20
140
11/6/03

Commissioner for Patents

Box 1450

Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants respectfully request that the publications relating to the above-mentioned application listed herein and on the accompanying PTO Form 1449 be considered by the Examiner and made of record in the U.S. Patent and Trademark Office.

NY02:434136.2

A34586 (070050.1668)
PATENT

1. International Patent Application No. PCT/US01/23099 by The Trustees of Columbia University entitled "Nucleic acids comprising regions of the rat PEG-3 promoter and uses thereof," published as WO 02/08242 on 31 January 2002.
2. International Patent Application No. PCT/US00/34564 by The Trustees of Columbia University entitled "Progression elevated gene-3 (PEG-3) induces aggressive cancer phenotype and regulates angiogenesis," published as WO 01/46386 on 28 June 2001.
3. United States Patent Publication 2001/0014734 by Fisher published August 16, 2001 and entitled "Progression elevated gene-3 and uses thereof."
4. United States Patent No. 6,146,877 by Fisher issued November 14, 2000 and entitled "Identification of the progression elevated gene-3 and uses thereof."
5. Gopalkrishnan RV, Christiansen KA, Goldstein NI, DePinho RA, Fisher PB (1999). Use of the human EF-1alpha promoter for expression can significantly increase success in establishing stable cell lines with consistent expression: a study using the tetracycline-inducible system in human cancer cells. *Nucleic Acids Res* 27:4775-4782.
6. International Patent Application No. PCT/US99/07199 by The Trustees of Columbia University entitled "Progression elevated gene-3 and uses thereof," published as WO 99/49898 on 7 October 1999.
7. International Patent Application No. PCT/US99/04323 by The Trustees of Columbia University entitled "Reciprocal subtraction differential display," published as WO 99/43844 on 2 September 1999.

A34586 (070050.1668)
PATENT

8. Su ZZ, Goldstein NI, Jiang H, Wang MN, Duigou GJ, Young CS, Fisher PB (1999). PEG-3, a nontransforming cancer progression gene, is a positive regulator of cancer aggressiveness and angiogenesis. *Proc Natl Acad Sci USA* 96:15115-15120.
9. United States Patent No. 5,882,874 by Fisher issued March 16, 1999 and entitled "Reciprocal subtraction differential display."
10. Ye M, Zhang QH, Zhou J, Shen Y, Wu XY, Guan ZQ, Wang L, Fan HY, Mao YF, Dai M, Huang QH, Chen SJ, Chen Z (1999). Homo sapiens HSPC280 mRNA. GenBank Accession No. AF161398. May 14, 1999.
11. Fisher PB (1998). PSCGen13. dbEST ID No. 1903240. GenBank Accession No. AI144570. November 23, 1998.
12. International Patent Application No. PCT/US98/05793 by The Trustees of Columbia University entitled "Identification of the progression elevated gene-3 and uses thereof," published as WO 98/42315 on 1 October 1998.
13. Kang DC, La France R, Su ZZ, Fisher PB (1998). Reciprocal subtraction differential RNA display (RSDD): an efficient and rapid procedure for isolating differentially expressed gene sequences. *Proc. Natl. Acad. Sci. USA* 95:13788-13793.
14. Zhang QH, Yu Y, Zhang S, Wei H, Zhou G, Ouyang S, Luo L, Bi J, Liu M, He F (1998). Homo sapiens PRO2013 mRNA. GenBank Accession No. AF116682. December 24, 1998.

A34586 (070050.1668)
PATENT

15. Strausberg R (1997). Hypothetical 18.3 kDa Protein. dbEST ID No. 3155305. EST wu69a04.x1. IMAGE Clone ID No. 2525262. GenBank Accession No. AW024795.
16. Su ZZ, Shi Y, Fisher PB (1997). Subtraction hybridization identifies a progression elevated gene PEG-3 with sequence homology to a growth arrest and DNA damage inducible gene. *Proc. Natl. Acad. Sci. USA* 94:9125-9130.
17. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB (1996). The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. *Proc Natl Acad Sci USA* 93:9160-9165.
18. Lee NH (1995). EST111677 derived from NGF-treated rat PC-12 cells. dbEST ID No. 295231. GenBank Accession No. H34607. July 19, 1995.
19. United States Patent No. 5,399,346 (Anderson *et al.*), issued March 21, 1995, entitled "Gene Therapy."
20. Knudson AG (1993). Antioncogenes and human cancer. *Proc Natl Acad Sci USA* 90:10914-10921.
21. Levine AJ (1993). The tumor suppressor genes. *Annu Rev Biochem* 62:623-651.
22. Reddy PG, Su ZZ, Fisher PB. In: *Chromosome and Genetic Analysis, Methods in Molecular Genetics*. Adolph KW, ed. Vol. I. Academic Press. 1993. pp. 68-102.
23. Vogelstein B, Kinzler KW (1993). The multistep nature of cancer. *Trends Genet* 9:138-141.
24. Anderson WF (1992). The June RAC meeting. *Hum. Gene Ther.* 3:459-460.

A34586 (070050.1668)
PATENT

25. Berkner KL (1992). Expression of heterologous sequences in adenoviral vectors. *Curr. Top. Microbiol. Immunol.* 158:39-66.
26. Bishop JM (1991). Molecular themes in oncogenesis. *Cell* 64:235-248.
27. Canonico AE, Conary JT, Christman BW, Meyrick BO, Brigham KL (1991). Expression of a CMV promoter driven human α -1 antitrypsin gene in cultured lung endothelial cells and in the lungs of rabbits. *Clin. Res.* 39:219A (abstract).
28. Culver KW, Anderson WF, Blaese RM (1991). Lymphocyte gene therapy. *Hum. Gene Ther.* 2:107-109.
29. Hazinski TA, Ladd PA, DeMatteo CA (1991). Localization and induced expression of fusion genes in the rat lung. *Am. J. Respir. Cell Mol. Biol.* 4:206-209.
30. Kaufman, RJ (1991). Vectors used for expression in mammalian cells. *Meth. Enzymol.* 185:487-511.
31. Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, Paakko PK, Gilardi P, Stratford-Perricaudet LD, Perricaudet M, *et al.* (1991). Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. *Science* 252:431-434.
32. Anderson WF, Blaese RM, Culver K (1990). The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. *Hum. Gene Ther.* 1:331-362.

A34586 (070050.1668)
PATENT

33. Duigou GJ, Babiss LE, Iman DS, Shay JW, Fisher PB (1990). Suppression of the progression phenotype in somatic cell hybrids occurs in the absence of altered adenovirus type 5 gene expression. *Mol Cell Biol* 10:2027-2034.
34. Geller AI, Keyomarsi K, Bryan J, Pardee AB (1990). An efficient deletion mutant packaging system for a defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. *Proc. Natl. Acad. Sci. USA* 87:8950-8954.
35. International Patent Application No. PCT/US90/01515 by Felgner *et al.* entitled "Expression of exogenous polynucleotide sequences in a vertebrate," published as WO 90/11092 on 4 October 1990.
36. Nabel EG, Plautz G, Nabel GJ (1990). Site-specific gene expression in vivo by direct gene transfer into the arterial wall. *Science* 249:1285-1288.
37. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990). Direct gene transfer into mouse muscle in vivo. *Science* 247:1465-1468.
38. Brigham KL, Meyrick B, Christman B, Magnuson M, King G, Berry LC Jr (1989). In vivo transfection of murine lungs with a functioning prokaryotic gene using a liposome vehicle. *Am. J. Med. Sci.* 298:278-281.
39. Duigou GJ, Babiss LE, Fisher PB (1989). Suppression of the progression phenotype by 5-azacytidine in rat embryo cells doubly transformed by type 5 adenovirus and the Ha-ras oncogene. *Annals NY Acad Sci* 567:302-306.

A34586 (070050.1668)
PATENT

40. Felgner PL, Holm M, Chan H (1989). Cationic liposome mediated transfection. *Proc. West. Pharmacol. Soc.* 32: 115-121.
41. Berkner KL (1988). Development of adenovirus vectors for the expression of heterologous genes. *BioTechniques* 6:616-629.
42. DePamphilis ML, Herman SA, Martinez-Salas E, Chalifour LE, Wirak DO, Cupo DY, Miranda M (1988). Microinjecting DNA into mouse ova to study DNA replication and gene expression and to produce transgenic animals. *BioTechniques* 6:662-680.
43. Guild BC, Finer MH, Housman DE, Mulligan RC (1988). Development of retrovirus vectors useful for expressing genes in cultured murine embryonic cells and hematopoietic cells in vivo. *J Virol.* 62:3795-3801.
44. McGrory WJ, Bautista DS, Graham FL (1988). A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. *Virology* 163(2):614-617.
45. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M (1987). Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. *Proc. Natl. Acad. Sci. USA* 84:7413-7417.
46. Ghosh-Choudhury G, Graham FL (1987). Stable transfer of a mouse dihydrofolate reductase gene into a deficient cell line using human adenovirus vector. *Biochem. Biophys. Res. Commun.* 147(3):964-973.

A34586 (070050.1668)
PATENT

47. Rossi P, de Crombrughe B (1987). Identification of a cell-specific transcriptional enhancer in the first intron of the mouse alpha 2 (type I) collagen gene. *Proc. Natl. Acad. Sci. USA* 84:5590-5594.
48. Ghosh-Choudhury G, Haj-Ahmad Y, Brinkley P, Rudy J, Graham FL (1986). Human adenovirus cloning vectors based on infectious bacterial plasmids. *Gene* 50:161-171.
49. Haj-Ahmad Y, Graham FL (1986). Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene. *J. Virol.* 57:267-274.
50. Hock RA, Miller AD (1986). Retrovirus mediated transfer and expression of drug resistance genes in human hemopoietic progenitor cells. *Nature* 320:275-277.
51. Stavridis JC, Deliconstantinos G, Psallidopoulos MC, Armenakas NA, Hadjiminis DJ, Hadjiminis J (1986). Construction of trans ferrin-coated liposomes for in vivo transport of exogenous DNA to bone marrow erythroblasts in rabbits. *Exp. Cell Res.* 164:568-572.
52. Wigand R, Adrian T (1986). Classification and epidemiology of adenoviruses. In: *Adenovirus DNA*. Doerfler W, ed. Martinus Nijhoff Pub., Boston. pp. 408-441.
53. Babiss LE, Zimmer SG, Fisher PB (1985). Reversibility of progression of the transformed phenotype in Ad5-transformed rat embryo cells. *Science* 228:1099-1101.
54. Kaufman RJ (1985). Identification of the component necessary for adenovirus translational control and their utilization in cDNA expression vectors. *Proc. Natl. Acad. Sci. USA* 82:689-693.

A34586 (070050.1668)
PATENT

55. Schmidt A, Setoyama C, de Crombrughe B (1985). Regulation of a collagen gene promoter by the product of viral mos oncogene. *Nature* 314:286-289.
56. Fisher PB (1984). Enhancement of viral transformation and expression of the transformed phenotype by tumor promoters. In: *Mechanisms of Tumor Promotion, Volume III. Tumor Promotion and Cocarcinogenesis In Vitro*. Slaga T, ed. CRC Press, Inc. 1984. pp. 57-123.
57. Van Doren K, Gluzman Y (1984). Efficient transformation of human fibroblasts by adenovirus-simian virus 40 recombinants. *Mol. Cell. Biol.* 4(8):1653-1656.
58. Berkner KL, Sharp PA (1983). Generation of adenovirus by transfection of plasmids. *Nucleic Acids Res.* 11(17):6003-6020.
59. Capecchi MR, Luciw PA, Bishop JM, Varmus HE (1983). Location and function of retroviral and SV40 sequences that enhance biochemical transformation after microinjection of DNA. In: *Enhancer and Eukaryotic Gene Expression*. Gluzman Y, Shenk T, eds. Cold Spring Harbor Laboratories. pp. 101-102.
60. Jolly DJ, Esty AC, Subramani S, Friedmann T, Verma IM (1983). Elements in the long terminal repeat of murine retroviruses enhance stable transformation by thymidine kinase gene. *Nucleic Acids Res.* 11:1855-1872.
61. Smith GL, Mackett M, Moss B (1983). Infectious vaccinia virus recombinants that express hepatitis B virus surface antigens. *Nature* 302:490-495.

A34586 (070050.1668)
PATENT

62. Panicali D, Paoletti E (1983). Construction of poxvirus as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccine virus. *Proc. Natl. Acad. Sci. USA* 79:4927-4931.
63. Fisher PB, Babiss LE, Weinstein IB, Ginsberg HS (1982). Analysis of type 5 adenovirus transformation with a cloned rat embryo cell line (CREF). *Proc Natl Acad Sci USA* 79:3527-3531.
64. Gluzman Y, Reichl H, Solnick D (1982). Helper-free adenovirus type-5 vectors. In: *Eukaryotic Viral Vectors*. Gluzman Y, ed. Cold Spring Harbor Laboratories. pp. 187-192.
65. Gorman CM, Moffat LF, Howard BH (1982). Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. *Mol. Cell. Biol.* 2(9):1044-1051.
66. Schaefer-Ridder M, Wang Y, Hofschneider PH (1982). Liposomes as gene carriers: Efficient transduction of mouse L cells by thymidine kinase gene. *Science* 215:166-168.
67. Banerji J, Rusconi S, Schaffner W (1981). Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences. *Cell* 27:299-308.
68. Breathnach R, Chambon P (1981). Organization and expression of eucaryotic split genes coding for proteins. *Ann. Rev. Biochem.* 50:349-383.
69. Colbere-Garapin F, Horodniceanu F, Kourilsky P, Garapin AC (1981) A new dominant hybrid selective marker for higher eukaryotic cells. *J. Mol. Biol.* 150:1-14.

A34586 (070050.1668)
PATENT

70. Mulligan RC, Berg P (1981). Selection for animal cells that express the *Escherichia coli* gene coding for xanthine-guanine phosphoribosyltransferase. *Proc. Natl. Acad. Sci. USA* 78:2072-2076.
71. Ringold G, Dieckmann B, Lee F (1981). Co-expression and amplification of dihydrofolate reductase cDNA and the *Escherichia coli* XGPRT gene in Chinese hamster ovary cells. *J. Mol. Appl. Genet.* 1:165-175.
72. Sarver N, Gruss P, Law MF, Khoury G, Howley PM (1981). Bovine papilloma virus DNA: a novel eukaryotic cloning vector. *Mol. Cell Biol.* 1:486-496.
73. Corden J, Waslyk B, Buchwalder A, Sassone-Corsi P, Keding C, Chambon P (1980). Promoter sequences of eukaryotic protein-coding genes. *Science* 209:1406-1414.
74. Urlaub G, Chasin LA (1980). Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. *Proc. Natl. Acad. Sci. USA* 77:4216-4220.
75. Fisher PB, Bozzone JH, Weinstein IB (1979). Tumor promoters and epidermal growth factor stimulate anchorage-independent growth of adenovirus-transformed rat embryo cells. *Cell* 18:695-705.
76. Fisher PB, Dorsch-Hasler K, Weinstein IB, Ginsberg HS (1979). Tumour promoters enhance anchorage-independent growth of adenovirus-transformed cells without altering the integration pattern of viral sequences. *Nature* 281:591-594.

A34586 (070050.1668)
PATENT

77. Fisher PB, Goldstein NL, Weinstein IB (1979). Phenotypic properties and tumor promotor-induced alterations in rat embryo cells transformed by adenovirus. *Cancer Res* 39:3051-3057.
78. Fisher PB, Weinstein IB, Eisenberg D, Ginsberg HS (1978). Interactions between adenovirus, a tumor promoter, and chemical carcinogens in transformation of rat embryo cell cultures. *Proc Natl Acad Sci USA* 75:2311-2314.
79. Bacchetti S, Graham FL (1977). Transfer of gene for thymidine kinase-deficient human cells by purified herpes simplex viral DNA. *Proc. Natl. Acad. Sci. USA* 74:1590-1594.
80. Fowler AV, Zabin I (1977). The amino acid sequence of beta-galactosidase of *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* 74(4):1507-1510.
81. Tu SC, Waters CA, Hastings JW (1975). Photoexcited bacterial bioluminescence. Identity and properties of the photoexcitable luciferase. *Biochemistry* 14(9):1970-1974.
82. Armelin HA (1973). Pituitary extracts and steroid hormones in the control of 3T3 cell growth. *Proc. Natl. Acad. Sci. USA* 70:2702-2706.
83. Graham FL, van der Eb AJ (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. *Virology* 52:456-467.
84. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966). Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. *Cancer Chemother. Rep.* 50:219-244.


A34586 (070050.1668)
PATENT

The submission of this Information Disclosure Statement does not represent that a search has been made or that no better art exists and does not constitute an admission that any of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Applicants believe that a fee of \$180.00 is due in connection with the filing of this Information Disclosure Statement and a check in that amount is enclosed. If any additional fee is due or overpayment is made with regard to this communication, the Commissioner is authorized to charge any such fee, and to credit any overpayment, to our Deposit Account No. 02-4377. Two copies of this communication are enclosed.

Respectfully submitted,



Lisa B. Kole

Patent Office Reg. No. 35,225

Attorney for Applicants
(212) 408-2628

Enclosures

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A34586 - 070050.1668	Serial No. 09/648,310
	Applicant Fisher <i>et al.</i>	
	Filing Date August 25, 2000	Group 1642
	Examiner Yu, M.	

Exam. Init.	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	5.	Gopalkrishnan RV, Christiansen KA, Goldstein NI, DePinho RA, Fisher PB (1999). Use of the human EF-1alpha promoter for expression can significantly increase success in establishing stable cell lines with consistent expression: a study using the tetracycline-inducible system in human cancer cells. <i>Nucleic Acids Res</i> 27:4775-4782.
	8.	Su ZZ, Goldstein NI, Jiang H, Wang MN, Duigou GJ, Young CS, Fisher PB (1999). PEG-3, a nontransforming cancer progression gene, is a positive regulator of cancer aggressiveness and angiogenesis. <i>Proc Natl Acad Sci USA</i> 96:15115-15120.
	10.	Ye M, Zhang QH, Zhou J, Shen Y, Wu XY, Guan ZQ, Wang L, Fan HY, Mao YF, Dai M, Huang QH, Chen SJ, Chen Z (1999). Homo sapiens HSPC280 mRNA. GenBank Accession No. AF161398. May 14, 1999.
	11.	Fisher PB (1998). PGen13. dbEST ID No. 1903240. GenBank Accession No. AI144570. November 23, 1998.
	13.	Kang DC, La France R, Su ZZ, Fisher PB (1998). Reciprocal subtraction differential RNA display (RSDD): an efficient and rapid procedure for isolating differentially expressed gene sequences. <i>Proc. Natl. Acad. Sci. USA</i> 95:13788-13793.
	14.	Zhang QH, Yu Y, Zhang S, Wei H, Zhou G, Ouyang S, Luo L, Bi J, Liu M, He F (1998). Homo sapiens PRO2013 mRNA. GenBank Accession No. AF116682. December 24, 1998.
	15.	Strausberg R (1997). Hypothetical 18.3 kDa Protein. dbEST ID No. 3155305. EST wu69a04.x1. IMAGE Clone ID No. 2525262. GenBank Accession No. AW024795.

NY02:443253.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A34586 - 070050.1668	Serial No. 09/648,310
	Applicant Fisher <i>et al.</i>	
	Filing Date August 25, 2000	Group 1642
	Examiner Yu, M.	

*Exam. Init.	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	16.	Su ZZ, Shi Y, Fisher PB (1997). Subtraction hybridization identifies a progression elevated gene PEG-3 with sequence homology to a growth arrest and DNA damage inducible gene. Proc. Natl. Acad. Sci. USA <u>94</u> :9125-9130.
	17.	Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB (1996). The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci USA <u>93</u> :9160-9165.
	18.	Lee NH (1995). EST111677 derived from NGF-treated rat PC-12 cells. dbEST ID No. 295231. GenBank Accession No. H34607. July 19, 1995.
	20.	Knudson AG (1993). Antioncogenes and human cancer. Proc Natl Acad Sci USA <u>90</u> :10914-10921.
	21.	Levine AJ (1993). The tumor suppressor genes. Annu Rev Biochem <u>62</u> :623-651.
	22.	Reddy PG, Su ZZ, Fisher PB. In: Chromosome and Genetic Analysis, Methods in Molecular Genetics. Adolph KW, ed. Vol. I. Academic Press. 1993. pp. 68-102.
	23.	Vogelstein B, Kinzler KW (1993). The multistep nature of cancer. Trends Genet <u>9</u> :138-141.
	24.	Anderson WF (1992). The June RAC meeting. Hum. Gene Ther. <u>3</u> :459-460.
	25.	Berkner KL (1992). Expression of heterologous sequences in adenoviral vectors. Curr. Top. Microbiol. Immunol. <u>158</u> :39-66.
	26.	Bishop JM (1991). Molecular themes in oncogenesis. Cell <u>64</u> :235-248.
	27.	Canonico AE, Conary JT, Christman BW, Meyrick BO, Brigham KL (1991). Expression of a CMV promoter driven human α -1 antitrypsin gene in cultured lung endothelial cells and in the lungs of rabbits. Clin. Res. <u>39</u> :219A (abstract).
	28.	Culver KW, Anderson WF, Blaese RM (1991). Lymphocyte gene therapy. Hum. Gene Ther. <u>2</u> :107-109.
NY02:443253.1		
Examiner		Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34586 - 070050.1668	Serial No. 09/648,310
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date August 25, 2000	Group 1642
	Examiner Yu, M.	

Exam. Init.	No.	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	29.	Hazinski TA, Ladd PA, DeMatteo CA (1991). Localization and induced expression of fusion genes in the rat lung. <i>Am. J. Respir. Cell Mol. Biol.</i> 4:206-209.
	30.	Kaufman, RJ (1991). Vectors used for expression in mammalian cells. <i>Meth. Enzymol.</i> 185:487-511.
	31.	Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, Paakko PK, Gilardi P, Stratford-Perricaudet LD, Perricaudet M, <i>et al.</i> (1991). Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. <i>Science</i> 252:431-434.
	32.	Anderson WF, Blaese RM, Culver K (1990). The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. <i>Hum. Gene Ther.</i> 1:331-362.
	33.	Duigou GJ, Babiss LE, Iman DS, Shay JW, Fisher PB (1990). Suppression of the progression phenotype in somatic cell hybrids occurs in the absence of altered adenovirus type 5 gene expression. <i>Mol Cell Biol</i> 10:2027-2034.
	34.	Geller AI, Keyomarsi K, Bryan J, Pardee ANTIBODY (1990). An efficient deletion mutant packaging system for a defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. <i>Proc. Natl. Acad. Sci. USA</i> 87:8950-8954.
	36.	Nabel EG, Plautz G, Nabel GJ (1990). Site-specific gene expression in vivo by direct gene transfer into the arterial wall. <i>Science</i> 249:1285-1288.
	37.	Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990). Direct gene transfer into mouse muscle in vivo. <i>Science</i> 247:1465-1468.
	38.	Brigham KL, Meyrick B, Christman B, Magnuson M, King G, Berry LC Jr (1989). In vivo transfection of murine lungs with a functioning prokaryotic gene using a liposome vehicle. <i>Am. J. Med. Sci.</i> 298:278-281.
	39.	Duigou GJ, Babiss LE, Fisher PB (1989). Suppression of the progression phenotype by 5-azacytidine in rat embryo cells doubly transformed by type 5 adenovirus and the Ha-ras oncogene. <i>Annals NY Acad Sci</i> 567:302-306.

NY02:443253.1	
Examiner	Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34586 - 070050.1668	Serial No. 09/648,310
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date August 25, 2000	Group 1642
	Examiner Yu, M.	

*Exam. Init	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	40.	Felgner PL, Holm M, Chan H (1989). Cationic liposome mediated transfection. Proc. West. Pharmacol. Soc. <u>32</u> : 115-121.
	41.	Berkner KL (1988). Development of adenovirus vectors for the expression of heterologous genes. BioTechniques <u>6</u> :616-629.
	42.	DePamphilis ML, Herman SA, Martinez-Salas E, Chalifour LE, Wirak DO, Cupo DY, Miranda M (1988). Microinjecting DNA into mouse ova to study DNA replication and gene expression and to produce transgenic animals. BioTechniques <u>6</u> :662-680.
	43.	Guild BC, Finer MH, Housman DE, Mulligan RC (1988). Development of retrovirus vectors useful for expressing genes in cultured murine embryonic cells and hematopoietic cells in vivo. J Virol. <u>62</u> :3795-3801.
	44.	McGrory WJ, Bautista DS, Graham FL (1988). A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology <u>163</u> (2):614-617.
	45.	Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M (1987). Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA <u>84</u> :7413-7417.
	46.	Ghosh-Choudhury G, Graham FL (1987). Stable transfer of a mouse dihydrofolate reductase gene into a deficient cell line using human adenovirus vector. Biochem. Biophys. Res. Commun. <u>147</u> (3):964-973.
	47.	Rossi P, de Crombrughe B (1987). Identification of a cell-specific transcriptional enhancer in the first intron of the mouse alpha 2 (type I) collagen gene. Proc. Natl. Acad. Sci. USA <u>84</u> :5590-5594.
	48.	Ghosh-Choudhury G, Haj-Ahmad Y, Brinkley P, Rudy J, Graham FL (1986). Human adenovirus cloning vectors based on infectious bacterial plasmids. Gene <u>50</u> :161-171.

NY02:443253.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A34586 - 070050.1668	Serial No. 09/648,310
	Applicant Fisher <i>et al.</i>	
	Filing Date August 25, 2000	Group 1642
	Examiner Yu, M.	

Exam. Init.	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	49.	Haj-Ahmad Y, Graham FL (1986). Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene. <i>J. Virol.</i> <u>57</u> :267-274.
	50.	Hock RA, Miller AD (1986). Retrovirus mediated transfer and expression of drug resistance genes in human hemopoietic progenitor cells. <i>Nature</i> <u>320</u> :275-277.
	51.	Stavridis JC, Deliconstantinos G, Psallidopoulos MC, Armenakas NA, Hadjiminis DJ, Hadjiminis J (1986). Construction of trans ferrin-coated liposomes for in vivo transport of exogenous DNA to bone marrow erythroblasts in rabbits. <i>Exp. Cell Res.</i> <u>164</u> :568-572.
	52.	Wigand R, Adrian T (1986). Classification and epidemiology of adenoviruses. In: <i>Adenovirus DNA</i> . Doerfler W, ed. Martinus Nijhoff Pub., Boston. pp. 408-441.
	53.	Babiss LB, Zimmer SG, Fisher PB (1985). Reversibility of progression of the transformed phenotype in Ad5-transformed rat embryo cells. <i>Science</i> <u>228</u> :1099-1101.
	54.	Kaufman RJ (1985). Identification of the component necessary for adenovirus translational control and their utilization in cDNA expression vectors. <i>Proc. Natl. Acad. Sci. USA</i> <u>82</u> :689-693.
	55.	Schmidt A, Setoyama C, de Crombrughe B (1985). Regulation of a collagen gene promoter by the product of viral mos oncogene. <i>Nature</i> <u>314</u> :286-289.
	56.	Fisher PB (1984). Enhancement of viral transformation and expression of the transformed phenotype by tumor promoters. In: <i>Mechanisms of Tumor Promotion, Volume III. Tumor Promotion and Cocarcinogenesis In Vitro</i> . Slaga T, ed. CRC Press, Inc. 1984. pp. 57-123.
	57.	Van Doren K, Gluzman Y (1984). Efficient transformation of human fibroblasts by adenovirus-simian virus 40 recombinants. <i>Mol. Cell. Biol.</i> <u>4</u> (8):1653-1656.
	58.	Berkner KL, Sharp PA (1983). Generation of adenovirus by transfection of plasmids. <i>Nucleic Acids Res.</i> <u>11</u> (17):6003-6020.

NY02:443253.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34586 - 070050.1668	Serial No. 09/648,310
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date August 25, 2000	Group 1642
	Examiner Yu, M.	

Exam. Init.	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	59.	Capeocchi MR, Luciw PA, Bishop JM, Varmus HE (1983). Location and function of retroviral and SV40 sequences that enhance biochemical transformation after microinjection of DNA. In: Enhancer and Eukaryotic Gene Expression. Gluzman Y, Shenk T, eds. Cold Spring Harbor Laboratories. pp. 101-102.
	60.	Jolly DJ, Esty AC, Subramani S, Friedmann T, Verma IM (1983). Elements in the long terminal repeat of murine retroviruses enhance stable transformation by thymidine kinase gene. Nucleic Acids Res. <u>11</u> :1855-1872.
	61.	Smith GL, Mackett M, Moss B (1983). Infectious vaccinia virus recombinants that express hepatitis B virus surface antigens. Nature <u>302</u> :490-495.
	62.	Panicali D, Paoletti E (1983). Construction of poxvirus as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccine virus. Proc. Natl. Acad. Sci. USA <u>79</u> :4927-4931.
	63.	Fisher PB, Babiss LE, Weinstein IB, Ginsberg HS (1982). Analysis of type 5 adenovirus transformation with a cloned rat embryo cell line (CREF). Proc Natl Acad Sci USA <u>79</u> :3527-3531.
	64.	Gluzman Y, Reichl H, Solnick D (1982). Helper-free adenovirus type-5 vectors. In: Eukaryotic Viral Vectors. Gluzman Y, ed. Cold Spring Harbor Laboratories. pp. 187-192.
	65.	Gorman CM, Moffat LF, Howard BH (1982). Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. <u>2</u> (9):1044-1051.
	66.	Schaefer-Ridder M, Wang Y, Hofschneider PH (1982). Liposomes as gene carriers: Efficient transduction of mouse L cells by thymidine kinase gene. Science <u>215</u> :166-168.
	67.	Banerji J, Rusconi S, Schaffner W (1981). Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences. Cell <u>27</u> :299-308.
	68.	Breathnach R, Chambon P (1981). Organization and expression of eucaryotic split genes coding for proteins. Ann. Rev. Biochem. <u>50</u> :349-383.

NY02:443253.1	
Examiner	Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34586 - 070050.1668	Serial No. 09/648,310
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date August 25, 2000	Group 1642
	Examiner Yu, M.	

*Exam. Init.	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	69.	Colbere-Garapin F, Horodniceanu F, Kourilsky P, Garapin AC (1981) A new dominant hybrid selective marker for higher eukaryotic cells. J. Mol. Biol. <u>150</u> :1-14.
	70.	Mulligan RC, Berg P (1981). Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase. Proc. Natl. Acad. Sci. USA <u>78</u> :2072-2076.
	71.	Ringold G, Dieckmann B, Lee F (1981). Co-expression and amplification of dihydrofolate reductase cDNA and the Escherichia coli XGPRT gene in Chinese hamster ovary cells. J. Mol. Appl. Genet. <u>1</u> :165-175.
	72.	Sarver N, Gruss P, Law MF, Khoury G, Howley PM (1981). Bovine papilloma virus DNA: a novel eukaryotic cloning vector. Mol. Cell Biol. <u>1</u> :486-496.
	73.	Corden J, Wasylyk B, Buchwalder A, Sassone-Corsi P, Kedinger C, Chambon P (1980). Promoter sequences of eukaryotic protein-coding genes. Science <u>209</u> :1406-1414.
	74.	Urlaub G, Chasin LA (1980). Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc. Natl. Acad. Sci. USA <u>77</u> :4216-4220.
	75.	Fisher PB, Bozzzone JH, Weinstein IB (1979). Tumor promoters and epidermal growth factor stimulate anchorage-independent growth of adenovirus-transformed rat embryo cells. Cell <u>18</u> :695-705.
	76.	Fisher PB, Dorsch-Hasler K, Weinstein IB, Ginsberg HS (1979). Tumour promoters enhance anchorage-independent growth of adenovirus-transformed cells without altering the integration pattern of viral sequences. Nature <u>281</u> :591-594.
	77.	Fisher PB, Goldstein NI, Weinstein IB (1979). Phenotypic properties and tumor promotor-induced alterations in rat embryo cells transformed by adenovirus. Cancer Res <u>39</u> :3051-3057.
	78.	Fisher PB, Weinstein IB, Eisenberg D, Ginsberg HS (1978). Interactions between adenovirus, a tumor promoter, and chemical carcinogens in transformation of rat embryo cell cultures. Proc Natl Acad Sci USA <u>75</u> :2311-2314.
NY02:443253.1		
Examiner		Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A34586 - 070050.1668	Serial N. 09/648,310
	Applicant Fisher <i>et al.</i>	
	Filing Date August 25, 2000	Group 1642
	Examiner Yu, M.	

*Exam. Init.	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	79.	Bacchetti S, Graham FL (1977). Transfer of gene for thymidine kinase-deficient human cells by purified herpes simplex viral DNA. Proc. Natl. Acad. Sci. USA <u>74</u> :1590-1594.
	80.	Fowler AV, Zabin I (1977). The amino acid sequence of beta-galactosidase of Escherichia coli. Proc. Natl. Acad. Sci. USA <u>74</u> (4):1507-1510.
	81.	Tu SC, Waters CA, Hastings JW (1975). Photoexcited bacterial bioluminescence. Identity and properties of the photoexcitable luciferase. Biochemistry <u>14</u> (9):1970-1974.
	82.	Armelin HA (1973). Pituitary extracts and steroid hormones in the control of 3T3 cell growth. Proc. Natl. Acad. Sci. USA <u>70</u> :2702-2706.
	83.	Graham FL, van der Eb AJ (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology <u>52</u> :456-467.
	84.	Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966). Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. <u>50</u> :219-244.

NY02:443253.1	
Examiner	Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.